On Friday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened higher 31.69% from the last session, before settling in for the closing price of $2.84. Price fluctuations for ZNTL have ranged from $1.01 to $3.06 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -12.89%. Company’s average yearly earnings per share was noted 21.73% at the time writing. With a float of $48.69 million, this company’s outstanding shares have now reached $72.25 million.
Zentalis Pharmaceuticals Inc (ZNTL) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 23.67%, while institutional ownership is 56.01%. The most recent insider transaction that took place on Dec 31 ’25, was worth 7,751,968. In this transaction 10% Owner of this company bought 6,459,973 shares at a rate of $1.20, taking the stock ownership to the 13,509,973 shares. Before that another transaction happened on Dec 15 ’25, when Company’s 10% Owner sold 7,500,000 for $1.33, making the entire transaction worth $9,975,000. This insider now owns 6,459,973 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.61 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.68) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.41% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 7.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.08, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -1.69 in one year’s time.
